Long-standing preservation of levodopa response in progressive supranuclear palsy

J Neurol Sci. 2024 Nov 15:466:123203. doi: 10.1016/j.jns.2024.123203. Epub 2024 Aug 29.

Abstract

The clinical and neuropathological characteristics of progressive supranuclear palsy (PSP) with preservation of levodopa (L-dopa) response are described in this report. We present the case of a 73-year-old Japanese man with a 13-year history of dopa-responsive Parkinsonism and abnormalities observed in metaiodobenzylguanidine (MIBG) myocardial scintigraphy, suggesting Parkinson's disease. However, autopsy results revealed PSP pathology, including tuft-shaped astrocytes and globose-type neurofibrillary tangles, without Lewy body pathology. The degeneration was moderately to severely distributed in the globus pallidus, subthalamic nucleus, and substantia nigra, whereas striatal degeneration was mild. These findings suggest an intact response to L-dopa therapy throughout the patient's lifetime. Pathological examination of cardiac sympathetic nerves revealed intact nerves, suggesting functional involvement in the MIBG abnormality. This study provides further evidence of the clinical and pathological heterogeneity of PSP. Homozygosity for both the rs564309-C allele at TRIM11 and the rs2242367-G allele at SLC2A13 might have played a protective role. This case indicates a protracted course-PSP, which may hold promise for future treatments.

Keywords: Neuropathology; Parkinson's disease; Preserved L-dopa responsivity; Protracted course-progressive supranuclear palsy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Humans
  • Levodopa* / therapeutic use
  • Male
  • Supranuclear Palsy, Progressive* / diagnostic imaging
  • Supranuclear Palsy, Progressive* / drug therapy
  • Supranuclear Palsy, Progressive* / genetics

Substances

  • Levodopa
  • Antiparkinson Agents